title: Potential target antigens for immunotherapy in human pancreatic cancer.
abstract: BACKGROUND
  To be effective and selective, immunotherapy ideally targets specifically tumor cells and spares normal tissues. Identification of tumor specific antigens is a prerequisite to establish an effective immunotherapy. Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms. Cancer Testis antigens (CT) are antigens shared by a variety of malignant tumors, but not by normal tissues with the exception of germ cells in testis. Restricted expression in neoplastic tissues and inherent immunogenic features make CT antigens ideal for use in immunotherapy. We analyzed the expression of a selected panel of nine CT antigens that have been proven to elicit an efficient immunogenic response in other malignancies. In addition we analyzed the expression of HERV-K-MEL, an immunogenic antigen of viral origin.
  
  
  METHODS
  Pancreatic adenocarcinoma tumor samples (n=130) were obtained intraoperatively, control tissues (n=23) were collected from cadaveric donor and from patients with chronic pancreatitis. Tumor-associated antigen expression of MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, LAGE-1, NY-ESO-1, SCP-1, SSX-2, SSX-4 and HERV-K-MEL was assessed by PCR. Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues.
  
  
  RESULTS
  Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples. SSX-4 was found positive in 30% of cases, SCP-1 in 19% and HERV-K-MEL in 23% of cases. No expression of CT antigens was found in non-malignant pancreatic tissue with the exception of SSX-4 and and SSX-2.
  
  
  CONCLUSIONS
  Fifty two percentage of the analyzed tissues expressed at least one CT antigen. The concomitant expression of SSX-4 in both malignant and non-malignant pancreatic tissue is a new finding which may raise concerns for immunotherapy. However, HERV-K-MEL is expressed with a relatively high prevalence and may be a candidate for specific immunotherapy in a large subgroup of pancreatic cancer patients. This study advocates the analysis of patients with regard to their immunogenic profile before the onset of antigen-specific immunotherapy.
authors.affiliation: Department of General Surgery, University Hospital of Heidelberg, Germany.
authors.forename: F H
authors.initials: FH
authors.lastname: Schmitz-Winnenthal
authors.forename: L V
authors.initials: LV
authors.lastname: Galindo-Escobedo
authors.forename: D
authors.initials: D
authors.lastname: Rimoldi
authors.forename: W
authors.initials: W
authors.lastname: Geng
authors.forename: P
authors.initials: P
authors.lastname: Romero
authors.forename: M
authors.initials: M
authors.lastname: Koch
authors.forename: J
authors.initials: J
authors.lastname: Weitz
authors.forename: R
authors.initials: R
authors.lastname: Krempien
authors.forename: A G
authors.initials: AG
authors.lastname: Niethammer
authors.forename: P
authors.initials: P
authors.lastname: Beckhove
authors.forename: M W
authors.initials: MW
authors.lastname: Buchler
authors.forename: K
authors.initials: K
authors.lastname: Z'graggen
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001374:Azacitidine / Q000008:administration & dosage; D001483:Base Sequence; D017931:DNA Primers; D006801:Humans; D007167:Immunotherapy; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000951:Antigens, Neoplasm; D017931:DNA Primers; D001374:Azacitidine